Bio Pharma Dive

AUGUST 23, 2022

At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.

RNA 335

RNA Medicine Drugs 335

Bio Pharma Dive

JULY 25, 2022

The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.

RNA 246

RNA Licensing Licensing Drugs 246

Bio Pharma Dive

AUGUST 30, 2021

Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus.

RNA 350

RNA 350

Bio Pharma Dive

OCTOBER 12, 2022

The startup, run by Translate Bio cofounder Romesh Subramanian, believes its RNA “exon editing” approach could have long-lasting effects without the risks that come with editing DNA.

RNA 261

RNA DNA 261

Pharmaceutical Technology

MARCH 1, 2023

Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.

RNA 147

RNA Vaccination Vaccine FDA Approval 147

Pharmaceutical Technology

APRIL 27, 2023

Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.

RNA 130

RNA Medicine Gene Therapy Gene 130

Bio Pharma Dive

NOVEMBER 9, 2021

The biotech is researching how to make medicines from transfer RNA molecules. Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.

RNA 359

RNA Medicine Drugs Research 359

Drug Discovery World

SEPTEMBER 18, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 52

RNA Drugs Research 52

Bio Pharma Dive

MAY 23, 2023

Staffed by many former Alnylam and Moderna employees, the startup is developing technologies that could be useful in a variety of RNA drugmaking methods.

RNA 196

RNA Drugs Development 196

Bio Pharma Dive

SEPTEMBER 7, 2022

“We see a huge opportunity in the setting of RNA-based therapies to overcome some of the shortcomings that have been there with the first generation of RNA companies,” said former Alnylam CEO and Orbital Therapeutics co-founder John Maraganore.

RNA 231

RNA Drugs 231

Bio Pharma Dive

MAY 10, 2021

Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines.

RNA 352

RNA Medicine 352

Bio Pharma Dive

JANUARY 11, 2022

Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more.

RNA 261

RNA Drugs Development 261

Bio Pharma Dive

JULY 6, 2021

The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs.

RNA 307

RNA Drugs Medicine 307

Drug Discovery World

SEPTEMBER 11, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 52

RNA Research Drugs 52

Roots Analysis

AUGUST 17, 2023

Genome sequencing has historically been classified into DNA sequencing and RNA sequencing. There are several RNA sequencing service providers coming in this market. In order to overcome these challenges, several stakeholders are focused on employing cutting edge technologies that can examine the quantity and sequences of RNA samples.

RNA 52

RNA DNA Genome Genomics 52

Pharmaceutical Technology

OCTOBER 11, 2022

Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. It also intends to turn the insights from its research into RNA-based drug candidates, and they will be tested in human livers at the company’s recently opened ‘Liver ICUs’ in the US.

RNA 130

RNA Gene Therapy Genome Genomics 130

Bio Pharma Dive

SEPTEMBER 8, 2021

The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen.

RNA 272

RNA Medicine Research 272

Bio Pharma Dive

FEBRUARY 17, 2022

The agreement with the Cambridge-based startup is the latest to reflect growing large pharma company interest in targeting RNA with small molecules.

RNA 201

RNA Pharma Companies Research 201

Drug Discovery World

AUGUST 28, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 52

RNA Drugs Research 52

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

Drug Discovery World

SEPTEMBER 4, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 52

RNA Drugs Research 52

Pharmaceutical Technology

JULY 29, 2022

Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. Their platform identifies which regRNAs control the specific gene of interest.

RNA 245

RNA Gene Expression Gene Therapy Gene 245

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147

RNA Vaccination Vaccine Gene Therapy 147

Drug Discovery World

JANUARY 23, 2023

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment. DS: How will your work ultimately impact disease treatment?

RNA 98

RNA Genome Genomics Drugs 98

Bio Pharma Dive

SEPTEMBER 19, 2023

AIRNA is one of several biotechs to debut plans for target alpha-1 antitrypsin deficiency in recent years, with competitors such as AlveoGene, Wave Life Sciences and Arrowhead Pharmaceuticals.

RNA 313

RNA Life Science 313

Drug Discovery World

AUGUST 3, 2023

Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital amaurosis 10 due to the c.2991+1655A>G The post Théa acquires ProQR’s RNA ophthalmic assets appeared first on Drug Discovery World (DDW). 2991+1655A>G mutation (p.Cys998X) in the CEP290 gene.

RNA 52

RNA Gene Drugs Development 52

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

Vaccination 345

Vaccination Vaccine RNA Trials 345

Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. This landscape is rapidly changing.

RNA 52

RNA Genome Genomics DNA 52

Drug Discovery World

AUGUST 25, 2023

In this roundtable, moderated by DDW and sponsored by Azenta Life Sciences, you will learn about the biggest challenges related to the delivery of RNA therapeutics. Philip Cruz Dr Neill Liptrott Reece Armstrong Panellists will address the following questions: How has the Covid-19 pandemic influenced the advancement of RNA research?

RNA 52

RNA Life Science Development Drugs 52

Bio Pharma Dive

JANUARY 6, 2021

The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules.

RNA 176

RNA Drugs Development 176

pharmaphorum

AUGUST 16, 2022

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 Now, Merck has made its own play, partnering with Orna on its proprietary ‘oRNA’ technology, which stands for circular RNA. billion, including $150 million upfront.

RNA 98

RNA Clinical Trials Clinical Trials Vaccination 98

Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. As tech experts call for improved regulation and a halt to the development of AI, we take a look at how one company, Atomic AI, is using it to develop RNA-targeting treatments for a range of diseases.

RNA 52

RNA Medicine Drugs Gene Therapy 52

Drug Discovery World

JUNE 7, 2023

Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. The post Grant supports discovery of RNA-targeting Henipavirus therapeutics appeared first on Drug Discovery World (DDW). Evotec has received a $1.7

RNA 52

RNA Antibody Vaccination Vaccine 52

pharmaphorum

NOVEMBER 1, 2022

14th Annual RNA Therapeutics. Investigating the next generation of genetic medicine through RNA based therapies. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. Date: 8 – 9 February 2023.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

Drug Discovery World

AUGUST 1, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The post RNA-based immunotherapy eradicates melanoma tumours appeared first on Drug Discovery World (DDW).

RNA 52

RNA Bioassay Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 9, 2021

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Over the last year, researchers have been studying the effectiveness of RNA-based pesticides, and there are already a handful of sprays in the works.

RNA 98

RNA Gene Protein Scientist 98

pharmaphorum

SEPTEMBER 15, 2023

6th RNA-Targeted Drug Discovery & Development Summit – December 12-14, Boston, MA Mike.Hammerton Fri, 15/09/2023 - 08:21 Bookmark this

RNA 52

RNA Drugs Development 52